Roughly two years ago, we put on our hardhats and went spelunking into the cavernous depths of the byzantine Medicare Part D plan cost share world to better understand and illustrate how the incentives created by the program’s design were bewilderingly injecting life into multi-source brands (i.e., “zombie brands”) and leading to warped, inflated pricing (and poor uptake) of their generic equivalents. We ventured down into these depths using Teva’s Copaxone as our case study, a blockbuster drug that treats certain types of multiple sclerosis (MS), and is no stranger to drama when it comes to pricing issues and patent games.